{
  "id": 20135497,
  "updated": "2019-02-18T19:03:06Z",
  "additionalIndexing": "15;2841",
  "affairType": {
    "abbreviation": "Qst.",
    "id": 14,
    "name": "Heure des questions. Question"
  },
  "author": {
    "councillor": {
      "code": 3011,
      "gender": "m",
      "id": 4099,
      "name": "Lehmann Markus",
      "officialDenomination": "Lehmann"
    },
    "faction": {
      "abbreviation": "Groupe CE",
      "id": 3,
      "name": "Groupe PDC-PEV"
    },
    "type": "author"
  },
  "deposit": {
    "council": {
      "abbreviation": "CN",
      "id": 1,
      "name": "Conseil national",
      "type": "N"
    },
    "date": "2013-11-27T00:00:00Z",
    "legislativePeriod": 49,
    "session": "4911"
  },
  "descriptors": [
    {
      "key": "L04K16020204",
      "name": "Forschungsförderung",
      "type": 1
    },
    {
      "key": "L03K160202",
      "name": "Forschungspolitik",
      "type": 1
    },
    {
      "key": "L03K010503",
      "name": "pharmazeutische Industrie",
      "type": 1
    },
    {
      "key": "L05K0704030111",
      "name": "Wirtschaftsstandort Schweiz",
      "type": 1
    },
    {
      "key": "L05K0105050101",
      "name": "Arzneikosten",
      "type": 1
    },
    {
      "key": "L05K0105030102",
      "name": "Medikament",
      "type": 2
    },
    {
      "key": "L04K11030304",
      "name": "Wechselkurs",
      "type": 2
    },
    {
      "key": "L04K11050311",
      "name": "Preisunterschied",
      "type": 2
    },
    {
      "key": "L04K08040103",
      "name": "Bundesamt für Gesundheit",
      "type": 2
    },
    {
      "key": "L04K01050512",
      "name": "medizinische Forschung",
      "type": 2
    }
  ],
  "drafts": [
    {
      "consultation": {
        "resolutions": [

        ]
      },
      "federalCouncilProposal": {
      },
      "index": 0,
      "links": [

      ],
      "preConsultations": [

      ],
      "references": [

      ],
      "relatedDepartments": [
        {
          "abbreviation": "DFI",
          "id": 4,
          "name": "Département de l'intérieur",
          "leading": true
        }
      ],
      "states": [
        {
          "date": "/Date(1385506800000+0100)/",
          "id": 24,
          "name": "Non encore traité au conseil"
        },
        {
          "date": "/Date(1385938800000+0100)/",
          "id": 27,
          "name": "Liquidé"
        }
      ],
      "texts": [

      ]
    }
  ],
  "handling": {
    "date": "2013-12-02T00:00:00Z",
    "legislativePeriod": 49,
    "session": "4911"
  },
  "language": "fr",
  "relatedAffairs": [

  ],
  "roles": [
    {
      "councillor": {
        "code": 3011,
        "gender": "m",
        "id": 4099,
        "name": "Lehmann Markus",
        "officialDenomination": "Lehmann"
      },
      "faction": {
        "abbreviation": "Groupe CE",
        "id": 3,
        "name": "Groupe PDC-PEV"
      },
      "type": "author"
    }
  ],
  "shortId": "13.5497",
  "state": {
    "id": 27,
    "name": "Liquidé",
    "doneKey": "1",
    "newKey": 0
  },
  "texts": [
    {
      "type": {
        "id": 5,
        "name": "Texte déposé"
      },
      "value": "<p>En adoptant la motion 11.3910, le Parlement a chargé en décembre 2011 le Conseil fédéral de présenter dans un délai de six mois un paquet de mesures pour consolider la position de la Suisse en tant que haut lieu de la recherche et de la production pharmaceutiques.</p><p>A cet égard:</p><p>- où en est aujourd'hui ce paquet de mesures?</p><p>- quand sera-t-il soumis au Parlement?</p>"
    },
    {
      "type": {
        "id": 1,
        "name": "Titre de l'objet"
      },
      "value": "Où en est la mise en oeuvre de la motion 11.3910?"
    }
  ],
  "title": "Où en est la mise en oeuvre de la motion 11.3910?"
}